Truist raised the firm’s price target on Amedisys (AMED) to $101 from $97 and keeps a Hold rating on the shares. The company’s pending deal with UnitedHealth Group/Optum (UNH) at $101 per share is a nice complement to UnitedHealth’s already strong home-based care platform, the analyst tells investors in a research note. The firm adds that it also remains bullish on underlying trends at standalone Option Care Health (OPCH) as Amedisys deal terminates that merger agreement.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMED:
- Amedisys price target raised to $101 from $88 at Barclays
- UNH Gains Slightly after Announcing New Merger Deal
- Option Care Health confirms termination of merger agreement with Amedisys
- Amedisys to combine with Optum in all-cash deal at $101 per share
- Amedisys and Optum to Combine, Advancing Value-Based Care for Patients